HIKAL
Hikal Limited
Pharmaceutical APIs and CDMO, crop protection and animal health chemicals manufacturer
Healthcare›Healthcare›Pharmaceuticals & Biotechnology›Pharmaceuticals
hikal.com(opens the company website in a new tab)Key metrics
Price as of 2026-10-16
Full years shown; sign in free for the trailing twelve months. Learn about these metrics →
Price & valuation
Share price and valuation multiples (P/E, P/B and more) over time.
Loading price history…
Compare with peers
Loading peers…
What you need to know
Hikal makes pharmaceutical ingredients and animal health products, and crop protection chemicals, for global drug and agrochemical companies, mostly as a contract development and manufacturing partner (CDMO) alongside some products of its own.
Company snapshot
71stBy market cap
Ranked among 119 companies in Pharmaceuticals.
Segment mix
Reportable segments as of 2024-12-31 (Consolidated). Revenue share = segment revenue ÷ total revenue.
Largest segment: 62.5% of revenue
| Segment | Revenue share | Revenue | PBT | Assets |
|---|---|---|---|---|
| Crop Protction | 37.5% | 491 Cr | 43 Cr | — |
| Pharmaceuticals | 62.5% | 817 Cr | 82 Cr | — |
| Unallocable | — | 0 Cr | 0 Cr | — |
What we see
- ✓94% of operating profit came in as cash over the last three years — profits are backed by real cash.
- ✗Net margin is negative — the company is spending more than it earns right now.
Statement tables · Consolidated
Switches quarterly, P&L, balance sheet, and cash flow. Key metrics and ratios stay on consolidated when available.
Amounts in ₹ Cr · tap + to expand rows
Quarterly results
Quarterly · ₹ Cr · tap + rows to expand
| Metric | Sept 2023 | Dec 2023 | Mar 2024 | Jun 2024 | Sept 2024 | Dec 2024 | Mar 2025 | Jun 2025 | Sept 2025 | Dec 2025 | Mar 2026 | Jun 2026 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Sales | 435 Cr | 448 Cr | 514 Cr | 407 Cr | 453 Cr | 448 Cr | 552 Cr | 380 Cr | 319 Cr | 494 Cr | 519 Cr | 403 Cr |
| Operating expenses (approx.) | 377 Cr | 383 Cr | 420 Cr | 349 Cr | 378 Cr | 376 Cr | 429 Cr | 355 Cr | 311 Cr | 412 Cr | 414 Cr | 366 Cr |
| EBITDA | 58 Cr | 65 Cr | 94 Cr | 58 Cr | 75 Cr | 72 Cr | 123 Cr | 25 Cr | 7 Cr | 83 Cr | 105 Cr | 37 Cr |
| OPM % | 13.2% | 14.5% | 18.4% | 14.3% | 16.5% | 16.1% | 22.3% | 6.6% | 2.3% | 16.7% | 20.3% | 9.2% |
| Other income | 0.99 Cr | 0.06 Cr | 0.46 Cr | 0.50 Cr | 0.40 Cr | 4 Cr | 0.50 Cr | 1 Cr | 2 Cr | 3 Cr | 7 Cr | 2 Cr |
| Interest | 13 Cr | 14 Cr | 15 Cr | 20 Cr | 19 Cr | 19 Cr | 18 Cr | 17 Cr | 15 Cr | 16 Cr | 15 Cr | 15 Cr |
| Depreciation | 29 Cr | 29 Cr | 32 Cr | 32 Cr | 32 Cr | 33 Cr | 38 Cr | 39 Cr | 41 Cr | 41 Cr | 42 Cr | 43 Cr |
| Profit before tax | 17 Cr | 22 Cr | 47 Cr | 7 Cr | 25 Cr | 24 Cr | 68 Cr | -30 Cr | -47 Cr | -9 Cr | 8 Cr | -10 Cr |
| Tax % | 25.4% | 25.3% | 28.2% | 26.1% | 26.2% | 27.7% | 26.5% | 26.3% | 25.7% | 35.9% | -73.5% | 25.3% |
| Net profit | 13 Cr | 16 Cr | 34 Cr | 5 Cr | 18 Cr | 17 Cr | 50 Cr | -22 Cr | -35 Cr | -6 Cr | 14 Cr | -7 Cr |
| EPS (₹) | ₹1.02 | ₹1.31 | ₹2.76 | ₹0.41 | ₹1.48 | ₹1.39 | ₹4.07 | ₹-1.82 | ₹-2.83 | ₹-0.48 | ₹1.17 | ₹-0.60 |
Profit & loss (annual)
Annual · last column is TTM · ₹ Cr · tap + to expand
| Metric | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 | TTM |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Sales | 1,034 Cr | 1,300 Cr | 1,590 Cr | 1,507 Cr | 1,720 Cr | 1,943 Cr | 2,023 Cr | 1,785 Cr | 1,860 Cr | 1,713 Cr | Sign in free for the trailing twelve months |
| Operating expenses (approx.) | 836 Cr | 1,058 Cr | 1,291 Cr | 1,234 Cr | 1,398 Cr | 1,602 Cr | 1,766 Cr | 1,518 Cr | 1,531 Cr | 1,492 Cr | Sign in free for the trailing twelve months |
| EBITDA | 198 Cr | 242 Cr | 298 Cr | 273 Cr | 323 Cr | 341 Cr | 257 Cr | 267 Cr | 328 Cr | 220 Cr | Sign in free for the trailing twelve months |
| OPM % | 19.2% | 18.6% | 18.8% | 18.1% | 18.8% | 17.5% | 12.7% | 15.0% | 17.7% | 12.9% | Sign in free for the trailing twelve months |
| Other income | 3 Cr | 4 Cr | 2 Cr | 4 Cr | 5 Cr | 5 Cr | 5 Cr | 2 Cr | 5 Cr | 12 Cr | Sign in free for the trailing twelve months |
| Interest | 48 Cr | 49 Cr | 58 Cr | 52 Cr | 36 Cr | 31 Cr | 48 Cr | 56 Cr | 75 Cr | 62 Cr | Sign in free for the trailing twelve months |
| Depreciation | 69 Cr | 86 Cr | 93 Cr | 82 Cr | 85 Cr | 96 Cr | 109 Cr | 118 Cr | 134 Cr | 164 Cr | Sign in free for the trailing twelve months |
| Profit before tax | 80 Cr | 112 Cr | 149 Cr | 127 Cr | 206 Cr | 219 Cr | 105 Cr | 96 Cr | 124 Cr | -78 Cr | Sign in free for the trailing twelve months |
| Tax % | 15.6% | 30.7% | 30.9% | 33.3% | 35.5% | 26.6% | 25.6% | 27.1% | 26.7% | 37.7% | Sign in free for the trailing twelve months |
| Net profit | 68 Cr | 77 Cr | 103 Cr | 84 Cr | 133 Cr | 161 Cr | 78 Cr | 70 Cr | 91 Cr | -49 Cr | Sign in free for the trailing twelve months |
| EPS (₹) | ₹8.19 | ₹9.40 | ₹8.36 | ₹6.85 | ₹10.80 | ₹13.02 | ₹6.36 | ₹5.64 | ₹7.36 | ₹-3.96 | Sign in free for the trailing twelve months |
| Dividend payout % | — | — | — | — | 11.1% | 16.9% | 15.7% | 21.3% | 16.3% | — | Sign in free for the trailing twelve months |
The latest four quarters added up, next to each full year
Balance sheet
Annual · ₹ Cr · tap + rows to expand
| Metric | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 |
|---|---|---|---|---|---|---|---|---|---|---|
| Equity capital | 16 Cr | 16 Cr | 25 Cr | 25 Cr | 25 Cr | 25 Cr | 25 Cr | 25 Cr | 25 Cr | 25 Cr |
| Reserves | 589 Cr | 653 Cr | 732 Cr | 792 Cr | 909 Cr | 1,043 Cr | 1,109 Cr | 1,163 Cr | 1,238 Cr | 1,174 Cr |
| Borrowings | 550 Cr | 574 Cr | 600 Cr | 561 Cr | 515 Cr | 674 Cr | 748 Cr | 815 Cr | 762 Cr | 681 Cr |
| Other liabilities | 224 Cr | 299 Cr | 330 Cr | 390 Cr | 465 Cr | 471 Cr | 504 Cr | 485 Cr | 504 Cr | 485 Cr |
| Total liabilities | 1,379 Cr | 1,542 Cr | 1,686 Cr | 1,768 Cr | 1,913 Cr | 2,213 Cr | 2,385 Cr | 2,487 Cr | 2,529 Cr | 2,365 Cr |
| Fixed assets (net) | 668 Cr | 630 Cr | 710 Cr | 733 Cr | 711 Cr | 815 Cr | 948 Cr | 1,060 Cr | 1,357 Cr | 1,327 Cr |
| CWIP | 62 Cr | 116 Cr | 73 Cr | 152 Cr | 245 Cr | 285 Cr | 402 Cr | 414 Cr | 121 Cr | 95 Cr |
| Investments | 4 Cr | 3 Cr | 1 Cr | 0.68 Cr | 0.61 Cr | 11 Cr | 5 Cr | 5 Cr | 10 Cr | 10 Cr |
| Loans & advances | — | — | 0.50 Cr | 0.36 Cr | 0.23 Cr | 0.31 Cr | 0.24 Cr | 0.53 Cr | 0.50 Cr | 0.30 Cr |
| Inventories | 264 Cr | 303 Cr | 364 Cr | 312 Cr | 267 Cr | 329 Cr | 317 Cr | 304 Cr | 335 Cr | 358 Cr |
| Trade receivables | 256 Cr | 287 Cr | 350 Cr | 340 Cr | 486 Cr | 438 Cr | 442 Cr | 550 Cr | 522 Cr | 442 Cr |
| Cash & bank | 2 Cr | 6 Cr | 11 Cr | 32 Cr | 8 Cr | 11 Cr | 27 Cr | 13 Cr | 13 Cr | 10 Cr |
| Other assets | 124 Cr | 197 Cr | 175 Cr | 197 Cr | 196 Cr | 324 Cr | 244 Cr | 140 Cr | 171 Cr | 125 Cr |
| Total assets | 1,379 Cr | 1,542 Cr | 1,686 Cr | 1,768 Cr | 1,913 Cr | 2,213 Cr | 2,385 Cr | 2,487 Cr | 2,529 Cr | 2,365 Cr |
Cash flows
Annual · ₹ Cr · tap + rows to expand · last column includes FCF
| Metric | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 |
|---|---|---|---|---|---|---|---|---|---|---|
| Cash from operating activity | 163 Cr | 139 Cr | 186 Cr | 285 Cr | 229 Cr | 294 Cr | 315 Cr | 187 Cr | 280 Cr | 302 Cr |
| Cash from investing | -102 Cr | -110 Cr | -125 Cr | -164 Cr | -156 Cr | -284 Cr | -292 Cr | -174 Cr | -136 Cr | -145 Cr |
| Cash from financing | -63 Cr | -25 Cr | -55 Cr | -101 Cr | -97 Cr | -6 Cr | -8 Cr | -27 Cr | -144 Cr | -160 Cr |
| Net cash flow | -2 Cr | 4 Cr | 6 Cr | 20 Cr | -24 Cr | 4 Cr | 15 Cr | -14 Cr | 0.30 Cr | -3 Cr |
| Free cash flow (OCF − Capex) | 41 Cr | 33 Cr | 57 Cr | 127 Cr | 229 Cr | 20 Cr | 13 Cr | -17 Cr | 143 Cr | 154 Cr |
Ratios
| Metric | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 |
|---|---|---|---|---|---|---|---|---|---|---|
| ROCE % | 11.1% | 12.9% | 15.3% | 13.0% | 16.7% | 14.3% | 8.2% | 7.6% | 9.8% | -0.9% |
| ROE % | 11.2% | 11.5% | 13.6% | 10.3% | 14.3% | 15.0% | 6.9% | 5.9% | 7.2% | -4.1% |
| Debtor days | 90 | 80 | 80 | 82 | 103 | 82 | 79 | 113 | 102 | 94 |
| Inventory days | 194 | 154 | 153 | 146 | 107 | 116 | 103 | 138 | 138 | 163 |
| Days payable | 96 | 84 | 67 | 94 | 92 | 88 | 102 | 127 | 125 | 121 |
| Cash conversion cycle | 188 | 151 | 165 | 134 | 118 | 110 | 81 | 124 | 115 | 136 |
| OCF / EBITDA % | 82.4% | 57.4% | 62.3% | 104.3% | 70.9% | 86.2% | 122.7% | 69.9% | 85.4% | 137.0% |
| OCF / EBITDA % (3 years) | — | — | 66.1% | 74.9% | 78.2% | 86.2% | 91.0% | 92.0% | 91.8% | 94.3% |
| Debt / equity | 0.91 | 0.86 | 0.79 | 0.69 | 0.55 | 0.63 | 0.66 | 0.69 | 0.60 | 0.57 |
| Current ratio | 1.31 | 1.23 | 1.38 | 1.30 | 1.34 | 1.25 | 1.42 | 1.28 | 1.26 | 1.30 |
| Net debt / EBITDA | 2.76 | — | 1.97 | 1.94 | 1.57 | 1.95 | 2.81 | 3.00 | 2.28 | 3.05 |